TherapeuticsMD Stock Price, News & Analysis (NASDAQ:TXMD)

$5.90 0.05 (0.85 %)
(As of 11/20/2017 04:00 PM ET)
Previous Close$5.85
Today's Range$5.77 - $5.97
52-Week Range$3.50 - $8.30
Volume2.06 million shs
Average Volume2.91 million shs
Market Capitalization$1.29 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.92

About TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD logoTherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.


Industry, Sector and Symbol:
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:TXMD
  • Previous Symbol: NYSEMKT:TXMD
  • CUSIP: N/A
  • Web: www.therapeuticsmd.com
Debt:
  • Current Ratio: 14.44%
  • Quick Ratio: 14.32%
Sales & Book Value:
  • Annual Sales: $19.36 million
  • Price / Sales: 65.95
  • Book Value: $0.65 per share
  • Price / Book: 9.08
Profitability:
  • Trailing EPS: ($0.39)
  • Net Income: ($89,870,000.00)
  • Net Margins: -457.00%
  • Return on Equity: -65.16%
  • Return on Assets: -58.66%
Misc:
  • Employees: 159
  • Outstanding Shares: 216,400,000
 

Frequently Asked Questions for TherapeuticsMD (NASDAQ:TXMD)

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD, Inc. (NASDAQ:TXMD) released its quarterly earnings data on Monday, November, 6th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.03. The firm earned $4.42 million during the quarter, compared to the consensus estimate of $5.36 million. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. The firm's quarterly revenue was down 19.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.13) earnings per share. View TherapeuticsMD's Earnings History.

Where is TherapeuticsMD's stock going? Where will TherapeuticsMD's stock price be in 2017?

11 Wall Street analysts have issued 1-year price objectives for TherapeuticsMD's shares. Their forecasts range from $6.00 to $33.00. On average, they anticipate TherapeuticsMD's share price to reach $14.72 in the next twelve months. View Analyst Ratings for TherapeuticsMD.

What are Wall Street analysts saying about TherapeuticsMD stock?

Here are some recent quotes from research analysts about TherapeuticsMD stock:

  • 1. According to Zacks Investment Research, "TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. " (8/10/2017)
  • 2. Jefferies Group LLC analysts commented, "TXMD and its expert speakers/consultants made convincing cases for TX-001 and '004 as differentiated and needed HRTs for VMS/VVA. With strong senior talent and sound marketing strategies, we believe '004 can take meaningful share (even without a clean label with no boxed safety warnings), while '001 can become the new standard of care, especially in the compounding pharmacy channel (with no competition). TXMD remains a top 2017 small-cap pick." (3/2/2017)

Are investors shorting TherapeuticsMD?

TherapeuticsMD saw a increase in short interest in October. As of October 31st, there was short interest totalling 55,856,043 shares, an increase of 35.8% from the October 13th total of 41,131,584 shares. Based on an average daily trading volume, of 2,240,090 shares, the days-to-cover ratio is currently 24.9 days. Currently, 32.1% of the shares of the company are sold short.

Who are some of TherapeuticsMD's key competitors?

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the folowing people:

  • Tommy G. Thompson J.D., Independent Chairman of the Board (Age 75)
  • John C. K. Milligan IV, President, Secretary, Director (Age 54)
  • Robert G. Finizio, Chief Executive Officer, Director (Age 46)
  • Daniel A. Cartwright, Chief Financial Officer, Treasurer (Age 59)
  • Mitchell L. Krassan, Executive Vice President, Chief Strategy Officer (Age 51)
  • Michael Donegan, Vice President - Finance (Age 49)
  • Brian Bernick M.D., Chief Clinical Officer, Director (Age 48)
  • Jules A. Musing, Director (Age 69)
  • J. Martin Carroll, Independent Director (Age 68)
  • Cooper C. Collins, Independent Director (Age 38)

Who owns TherapeuticsMD stock?

TherapeuticsMD's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (11.96%), JPMorgan Chase & Co. (10.18%), Gilder Gagnon Howe & Co. LLC (1.14%), Stifel Financial Corp (1.00%), Columbus Circle Investors (0.93%) and Bamco Inc. NY (0.43%). Company insiders that own TherapeuticsMD stock include Cooper C Collins and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD.

Who sold TherapeuticsMD stock? Who is selling TherapeuticsMD stock?

TherapeuticsMD's stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Point72 Asset Management L.P., Sphera Funds Management LTD., TD Asset Management Inc., Columbus Circle Investors, Stoneridge Investment Partners LLC, California State Teachers Retirement System and Jane Street Group LLC. View Insider Buying and Selling for TherapeuticsMD.

Who bought TherapeuticsMD stock? Who is buying TherapeuticsMD stock?

TherapeuticsMD's stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Bank of New York Mellon Corp, Alyeska Investment Group L.P., 1492 Capital Management LLC, ING Groep NV, GSA Capital Partners LLP, Bamco Inc. NY and Candriam Luxembourg S.C.A.. Company insiders that have bought TherapeuticsMD stock in the last two years include Cooper C Collins and Tommy G Thompson. View Insider Buying and Selling for TherapeuticsMD.

How do I buy TherapeuticsMD stock?

Shares of TherapeuticsMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TherapeuticsMD's stock price today?

One share of TherapeuticsMD stock can currently be purchased for approximately $5.90.

How big of a company is TherapeuticsMD?

TherapeuticsMD has a market capitalization of $1.29 billion and generates $19.36 million in revenue each year. The company earns ($89,870,000.00) in net income (profit) each year or ($0.39) on an earnings per share basis. TherapeuticsMD employs 159 workers across the globe.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 6800 Broken Sound Pkwy NW, BOCA RATON, FL 33487-2721, United States. The company can be reached via phone at +1-561-9611911 or via email at [email protected]


MarketBeat Community Rating for TherapeuticsMD (NASDAQ TXMD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  92 (Vote Outperform)
Underperform Votes:  79 (Vote Underperform)
Total Votes:  171
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for TherapeuticsMD (NASDAQ:TXMD)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 10 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.91)
Consensus Price Target: $14.72 (149.53% upside)

Consensus Price Target History for TherapeuticsMD (NASDAQ:TXMD)

Price Target History for TherapeuticsMD (NASDAQ:TXMD)

Analysts' Ratings History for TherapeuticsMD (NASDAQ:TXMD)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/6/2017Cowen and CompanyReiterated RatingOutperform$13.00 -> $16.00N/AView Rating Details
10/16/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$10.00N/AView Rating Details
9/26/2017Jefferies Group LLCReiterated RatingBuy$15.00MediumView Rating Details
9/13/2017Deutsche Bank AGReiterated RatingBuy$10.00MediumView Rating Details
9/8/2017Morgan StanleyInitiated CoverageEqual Weight$6.00N/AView Rating Details
9/4/2017Cantor FitzgeraldReiterated RatingBuy$33.00MediumView Rating Details
8/21/2017Stifel NicolausReiterated RatingBuy$20.00LowView Rating Details
8/4/2017Noble FinancialReiterated RatingBuyMediumView Rating Details
7/11/2017CIBCUpgradeMarket Perform -> OutperformHighView Rating Details
12/6/2016GuggenheimReiterated RatingPositiveN/AView Rating Details
12/4/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$10.50N/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for TherapeuticsMD (NASDAQ:TXMD)

Earnings by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Earnings History by Quarter for TherapeuticsMD (NASDAQ TXMD)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017($0.10)($0.07)$5.36 million$4.42 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.11)($0.10)$4.91 million$4.25 millionViewListenView Earnings Details
2/23/2017Q416($0.12)($0.12)$5.91 million$4.49 millionViewListenView Earnings Details
11/3/2016Q316($0.11)($0.13)$5.76 million$5.50 millionViewN/AView Earnings Details
8/4/2016Q216($0.10)($0.11)$5.63 million$4.40 millionViewN/AView Earnings Details
5/3/2016Q116($0.09)($0.11)$5.73 million$4.93 millionViewN/AView Earnings Details
2/25/2016Q415($0.10)($0.10)$5.33 million$5.63 millionViewListenView Earnings Details
11/4/2015Q315($0.12)($0.11)$5.01 million$5.19 millionViewN/AView Earnings Details
8/6/2015Q215($0.11)($0.16)$4.65 million$4.80 millionViewListenView Earnings Details
5/5/2015($0.10)($0.13)ViewN/AView Earnings Details
3/10/2015Q414($0.09)($0.10)$2.86 million$4.26 millionViewN/AView Earnings Details
11/6/2014Q3 14($0.08)($0.12)ViewN/AView Earnings Details
5/6/2014Q1 14($0.06)($0.06)$3.08 million$2.80 millionViewN/AView Earnings Details
3/3/2014Q213($0.06)($0.06)$2.72 million$2.90 millionViewN/AView Earnings Details
5/8/2013Q113($0.06)($0.06)$1.32 million$1.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for TherapeuticsMD (NASDAQ:TXMD)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20172($0.08)($0.08)($0.08)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for TherapeuticsMD (NASDAQ:TXMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for TherapeuticsMD (NASDAQ TXMD)

Insider Ownership Percentage: 23.92%
Institutional Ownership Percentage: 76.82%
Insider Trades by Quarter for TherapeuticsMD (NASDAQ:TXMD)
Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Insider Trades by Quarter for TherapeuticsMD (NASDAQ TXMD)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/30/2017Tommy G ThompsonDirectorBuy5,000$5.99$29,950.00View SEC Filing  
3/11/2016Cooper C CollinsDirectorBuy16,000$6.23$99,680.00View SEC Filing  
8/25/2015Angus C RussellDirectorBuy13,500$5.98$80,730.00View SEC Filing  
6/8/2015Mitchell KrassanEVPSell30,000$8.18$245,400.00View SEC Filing  
5/12/2015Angus C RussellDirectorBuy35,000$6.15$215,250.00View SEC Filing  
5/11/2015Tommy G ThompsonChairmanBuy6,000$6.09$36,540.00View SEC Filing  
5/8/2015J Martin CarrollDirectorBuy10,000$6.11$61,100.00View SEC Filing  
11/21/2014Daniel A CartwrightCFOSell40,000$3.91$156,400.00View SEC Filing  
9/4/2014Tommy G ThompsonDirectorBuy1,757$5.44$9,558.08View SEC Filing  
6/5/2014Cooper C CollinsDirectorBuy20,000$3.84$76,800.00View SEC Filing  
5/9/2014Robert Lapenta, Jr.DirectorBuy5,000$3.66$18,300.00View SEC Filing  
5/8/2014Tommy ThompsonDirectorBuy14,000$3.57$49,980.00View SEC Filing  
3/26/2014Brian BernickDirectorSell421,268$6.70$2,822,495.60View SEC Filing  
3/26/2014John C.K. Iv MilliganInsiderSell353,412$6.70$2,367,860.40View SEC Filing  
3/26/2014Robert FinizioCEOSell982,053$6.70$6,579,755.10View SEC Filing  
3/10/2014Mitchell KrassanEVPSell7,500$7.73$57,975.00View SEC Filing  
2/26/2014John C.K. Iv MilliganPresidentSell25,000$6.31$157,750.00View SEC Filing  
2/21/2014Robert FinizioCEOSell50,000$6.17$308,500.00View SEC Filing  
2/12/2014Brian BernickDirectorSell31,250$6.16$192,500.00View SEC Filing  
1/30/2014John C.K. Iv MilliganInsiderSell25,000$6.16$154,000.00View SEC Filing  
1/23/2014Robert G FinizioCEOSell50,000$5.70$285,000.00View SEC Filing  
1/13/2014Mitchell KrassanEVPSell7,500$5.73$42,975.00View SEC Filing  
1/8/2014Brian BernickDirectorSell31,250$5.13$160,312.50View SEC Filing  
8/26/2013Brian BernickInsiderSell1,600,000$1.55$2,480,000.00View SEC Filing  
8/26/2013Jules A MusingDirectorBuy5,282$2.15$11,356.30View SEC Filing  
6/14/2013Cooper C CollinsDirectorSell2,631,579$1.75$4,605,263.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for TherapeuticsMD (NASDAQ TXMD)

Source:
DateHeadline
Cantor Fitzgerald Analysts Boost Earnings Estimates for TherapeuticsMD, Inc. (TXMD)Cantor Fitzgerald Analysts Boost Earnings Estimates for TherapeuticsMD, Inc. (TXMD)
www.americanbankingnews.com - November 17 at 7:12 PM
Financial Review: Salix Pharmaceuticals (SLXP) vs. TherapeuticsMD (TXMD)Financial Review: Salix Pharmaceuticals (SLXP) vs. TherapeuticsMD (TXMD)
www.americanbankingnews.com - November 15 at 9:12 PM
Financial Comparison: TherapeuticsMD (TXMD) & Its RivalsFinancial Comparison: TherapeuticsMD (TXMD) & Its Rivals
www.americanbankingnews.com - November 15 at 3:30 PM
Head-To-Head Survey: TherapeuticsMD (TXMD) versus Its PeersHead-To-Head Survey: TherapeuticsMD (TXMD) versus Its Peers
www.americanbankingnews.com - November 13 at 11:22 PM
Financial Survey: TherapeuticsMD (TXMD) and Its PeersFinancial Survey: TherapeuticsMD (TXMD) and Its Peers
www.americanbankingnews.com - November 13 at 7:34 AM
TherapeuticsMD, Inc. (TXMD) Given Average Rating of "Buy" by AnalystsTherapeuticsMD, Inc. (TXMD) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - November 13 at 4:26 AM
Analyzing TherapeuticsMD (TXMD) and Its CompetitorsAnalyzing TherapeuticsMD (TXMD) and Its Competitors
www.americanbankingnews.com - November 12 at 9:52 AM
TherapeuticsMD (TXMD) & Its Competitors Critical ComparisonTherapeuticsMD (TXMD) & Its Competitors Critical Comparison
www.americanbankingnews.com - November 12 at 9:38 AM
Head to Head Survey: TherapeuticsMD (TXMD) vs. Its PeersHead to Head Survey: TherapeuticsMD (TXMD) vs. Its Peers
www.americanbankingnews.com - November 12 at 8:38 AM
 Analysts Expect TherapeuticsMD, Inc. (TXMD) Will Post Quarterly Sales of $4.67 Million Analysts Expect TherapeuticsMD, Inc. (TXMD) Will Post Quarterly Sales of $4.67 Million
www.americanbankingnews.com - November 12 at 6:38 AM
Head to Head Comparison: TherapeuticsMD (TXMD) and Its CompetitorsHead to Head Comparison: TherapeuticsMD (TXMD) and Its Competitors
www.americanbankingnews.com - November 11 at 11:26 PM
TherapeuticsMD, Inc. (TXMD) Short Interest UpdateTherapeuticsMD, Inc. (TXMD) Short Interest Update
www.americanbankingnews.com - November 11 at 1:50 AM
FY2017 Earnings Estimate for TherapeuticsMD, Inc. Issued By Cantor Fitzgerald (TXMD)FY2017 Earnings Estimate for TherapeuticsMD, Inc. Issued By Cantor Fitzgerald (TXMD)
www.americanbankingnews.com - November 10 at 12:40 PM
TherapeuticsMD, Inc. breached its 50 day moving average in a Bearish Manner : TXMD-US : November 9, 2017TherapeuticsMD, Inc. breached its 50 day moving average in a Bearish Manner : TXMD-US : November 9, 2017
finance.yahoo.com - November 9 at 8:55 AM
Oppenheimer Holdings Equities Analysts Decrease Earnings Estimates for TherapeuticsMD, Inc. (TXMD)Oppenheimer Holdings Equities Analysts Decrease Earnings Estimates for TherapeuticsMD, Inc. (TXMD)
www.americanbankingnews.com - November 9 at 6:22 AM
FY2019 EPS Estimates for TherapeuticsMD, Inc. (TXMD) Cut by AnalystFY2019 EPS Estimates for TherapeuticsMD, Inc. (TXMD) Cut by Analyst
www.americanbankingnews.com - November 8 at 9:52 PM
TherapeuticsMD, Inc. Forecasted to Post FY2017 Earnings of ($0.31) Per Share (TXMD)TherapeuticsMD, Inc. Forecasted to Post FY2017 Earnings of ($0.31) Per Share (TXMD)
www.americanbankingnews.com - November 8 at 10:36 AM
TherapeuticsMD to Present at Two Upcoming Investor ConferencesTherapeuticsMD to Present at Two Upcoming Investor Conferences
finance.yahoo.com - November 7 at 9:01 PM
TherapeuticsMD, Inc. Expected to Post FY2019 Earnings of $0.24 Per Share (TXMD)TherapeuticsMD, Inc. Expected to Post FY2019 Earnings of $0.24 Per Share (TXMD)
www.americanbankingnews.com - November 7 at 4:26 PM
Clinical Studies Elevating Biotech Drug Development to New Levels for Unmet Medical NeedsClinical Studies Elevating Biotech Drug Development to New Levels for Unmet Medical Needs
www.bizjournals.com - November 7 at 4:01 PM
TherapeuticsMD, Inc. (TXMD) Posts  Earnings Results, Beats Expectations By $0.03 EPSTherapeuticsMD, Inc. (TXMD) Posts Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - November 7 at 9:06 AM
Cowen and Company Reiterates Outperform Rating for TherapeuticsMD, Inc. (TXMD)Cowen and Company Reiterates Outperform Rating for TherapeuticsMD, Inc. (TXMD)
www.americanbankingnews.com - November 6 at 11:39 AM
Cowen and Company Reaffirms Outperform Rating for TherapeuticsMD, Inc. (TXMD)Cowen and Company Reaffirms Outperform Rating for TherapeuticsMD, Inc. (TXMD)
www.americanbankingnews.com - November 6 at 11:38 AM
Critical Review: TherapeuticsMD (TXMD) vs. Its CompetitorsCritical Review: TherapeuticsMD (TXMD) vs. Its Competitors
www.americanbankingnews.com - October 28 at 11:40 AM
TherapeuticsMD: Near Term Catalysts and Analysts ReviewTherapeuticsMD: Near Term Catalysts and Analysts Review
finance.yahoo.com - October 26 at 12:39 PM
TherapeuticsMD, Inc. (TXMD) Set to Announce Earnings on WednesdayTherapeuticsMD, Inc. (TXMD) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - October 25 at 7:49 AM
Short Interest in TherapeuticsMD, Inc. (TXMD) Increases By InfinityShort Interest in TherapeuticsMD, Inc. (TXMD) Increases By Infinity
www.americanbankingnews.com - October 25 at 1:04 AM
Head-To-Head Comparison: TherapeuticsMD (TXMD) & Its RivalsHead-To-Head Comparison: TherapeuticsMD (TXMD) & Its Rivals
www.americanbankingnews.com - October 24 at 8:50 PM
Financial Survey: TherapeuticsMD (TXMD) versus AbbVie (ABBV)Financial Survey: TherapeuticsMD (TXMD) versus AbbVie (ABBV)
www.americanbankingnews.com - October 24 at 10:45 AM
Contrasting TherapeuticsMD (TXMD) and The CompetitionContrasting TherapeuticsMD (TXMD) and The Competition
www.americanbankingnews.com - October 22 at 2:08 PM
Comparing TherapeuticsMD (TXMD) & Its CompetitorsComparing TherapeuticsMD (TXMD) & Its Competitors
www.americanbankingnews.com - October 22 at 10:10 AM
 Analysts Anticipate TherapeuticsMD, Inc. (TXMD) to Announce -$0.09 EPS Analysts Anticipate TherapeuticsMD, Inc. (TXMD) to Announce -$0.09 EPS
www.americanbankingnews.com - October 21 at 10:30 PM
Critical Analysis: TherapeuticsMD (TXMD) and The CompetitionCritical Analysis: TherapeuticsMD (TXMD) and The Competition
www.americanbankingnews.com - October 19 at 12:38 PM
TherapeuticsMD, Inc. (TXMD) Given Consensus Rating of "Buy" by BrokeragesTherapeuticsMD, Inc. (TXMD) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 19 at 2:34 AM
TherapeuticsMD (TXMD) Reports Nine Presentations Related to TX-004HR and TX-001HR at NAMS - StreetInsider.comTherapeuticsMD (TXMD) Reports Nine Presentations Related to TX-004HR and TX-001HR at NAMS - StreetInsider.com
www.streetinsider.com - October 6 at 12:00 PM
TherapeuticsMD, Inc. (Nasdaq: TXMD) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its Listing On ... - GlobeNewswire (press release)TherapeuticsMD, Inc. (Nasdaq: TXMD) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its Listing On ... - GlobeNewswire (press release)
globenewswire.com - October 6 at 12:00 PM
TherapeuticsMD Announces Multiple Presentations Related to TX-004HR and TX-001HR at NAMS 2017TherapeuticsMD Announces Multiple Presentations Related to TX-004HR and TX-001HR at NAMS 2017
finance.yahoo.com - October 6 at 11:59 AM
TherapeuticsMD, Inc. :TXMD-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017TherapeuticsMD, Inc. :TXMD-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 11:59 AM
TherapeuticsMD, Inc. (Nasdaq: TXMD) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its Listing On NasdaqTherapeuticsMD, Inc. (Nasdaq: TXMD) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its Listing On Nasdaq
finance.yahoo.com - October 6 at 11:59 AM
$5.03 Million in Sales Expected for TherapeuticsMD Inc (TXMD) This Quarter$5.03 Million in Sales Expected for TherapeuticsMD Inc (TXMD) This Quarter
www.americanbankingnews.com - October 5 at 2:40 PM
Head to Head Analysis: TherapeuticsMD (TXMD) versus AbbVie (ABBV)Head to Head Analysis: TherapeuticsMD (TXMD) versus AbbVie (ABBV)
www.americanbankingnews.com - September 29 at 2:30 AM
TherapeuticsMD (TXMD) Shares Cross Below 200 DMA - NasdaqTherapeuticsMD (TXMD) Shares Cross Below 200 DMA - Nasdaq
www.nasdaq.com - September 28 at 7:48 AM
Jefferies Group LLC Reiterates "Buy" Rating for TherapeuticsMD Inc (TXMD)Jefferies Group LLC Reiterates "Buy" Rating for TherapeuticsMD Inc (TXMD)
www.americanbankingnews.com - September 26 at 6:56 PM
Heres Why TherapeuticsMD Inc Is Falling Today Here's Why TherapeuticsMD Inc Is Falling Today
www.fool.com - September 26 at 1:32 PM
TherapeuticsMD Inc (TXMD) Receives Consensus Recommendation of "Buy" from AnalystsTherapeuticsMD Inc (TXMD) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 24 at 2:38 AM
Analyzing Eagle Pharmaceuticals (EGRX) and TherapeuticsMD (TXMD)Analyzing Eagle Pharmaceuticals (EGRX) and TherapeuticsMD (TXMD)
www.americanbankingnews.com - September 16 at 10:32 AM
Deutsche Bank AG Reiterates Buy Rating for TherapeuticsMD Inc (TXMD)Deutsche Bank AG Reiterates Buy Rating for TherapeuticsMD Inc (TXMD)
www.americanbankingnews.com - September 13 at 9:52 AM
Reviewing TherapeuticsMD (TXMD) and Mallinckrodt PLC (MNK)Reviewing TherapeuticsMD (TXMD) and Mallinckrodt PLC (MNK)
www.americanbankingnews.com - September 9 at 8:32 AM
TherapeuticsMD Inc (TXMD) Given "Buy" Rating at Jefferies Group LLCTherapeuticsMD Inc (TXMD) Given "Buy" Rating at Jefferies Group LLC
www.americanbankingnews.com - September 8 at 9:52 PM
TherapeuticsMD Inc (TXMD) Coverage Initiated at Morgan StanleyTherapeuticsMD Inc (TXMD) Coverage Initiated at Morgan Stanley
www.americanbankingnews.com - September 8 at 8:20 AM

Social Media

Financials

Chart

TherapeuticsMD (NASDAQ TXMD) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.